Chapter 5- Acute Coronary Syndrome

Description

IMPORTANT NOTE – PLEASE READ FIRST: This continuing education assessment requires that you first purchase the text book: Pharmacotherapy Principles & Practice. Please go to our home page: http://www.rxugace.com/ and click on “Books” for more information Prior To Registering for this assessment.

Upon completion of the corresponding textbook chapter in Pharmacotherapy Principles & Practice and this on-line assessment, the reader should be able to:

1. Define the role of an atherosclerotic plaque, platelets, and coagulation system in an acute coronary syndrome.
2. Describe the onset, peak, and duration of elevation of troponin and creatine kinase myocardial band in acute myocardial infarction.
3. List key electrocardiographic and clinical features identifying a patient with non–ST-segment elevation acute coronary syndrome who is at high risk of myocardial infarction or death.
4. Devise a pharmacotherapy treatment plan for a patient undergoing primary percutaneous coronary intervention in ST-segment elevation myocardial infarction given patient-specific data.
5. Devise a pharmacotherapy treatment plan for a patient with ST-segment elevation myocardial infarction given patient-specific data.
6. List the quality indicators of care for myocardial infarction and explain the rationale behind each indicator.
7. Formulate a monitoring plan for a patient with ST-segment elevation acute coronary syndrome receiving fibrinolytics, aspirin, unfractionated heparin, intravenous nitroglycerin, intravenous -blockers followed by oral -blockers, an angiotensin-converting enzyme inhibitor, and a statin.
8. Devise a pharmacotherapy treatment plan for a patient with non–ST-segment elevation acute coronary syndrome given patient-specific data.
9. Formulate a monitoring plan for a patient with non–ST-segment elevation acute coronary syndrome receiving aspirin, clopidogrel, enoxaparin, intravenous nitroglycerin, intravenous -blockers followed by oral -blockers, an angiotensin-converting enzyme inhibitor, and a statin.
10. Devise a pharmacotherapy and risk-factor modification treatment plan for secondary prevention of coronary heart disease events in a patient following myocardial infarction.

Courses Offered